Brief: Inhibikase Therapeutics Receives FDA Orphan Drug Designation For The Treatment Of Multiple System Atrophy
04/10/2023 13:47
Oct 4 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS RECEIVES FDA ORPHAN DRUG
DESIGNATION FOR
RISVODETINIB FOR THE TREATMENT OF MULTIPLE SYSTEM ATROPHY
Source text for Eikon: ID:nGNX2JGZvP
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary